Search - tctmd.com

Displaying 1 - 20 of 2795

Sort: Relevancy | Date

News Daily News

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

Todd Neale

January 25, 2016

Presentation TCT 2013

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Presenter: Rakesh Sharma, Stephen Erickson, Rohit Sharma, Hanumanth Reddy, Donald Voelker, Harvinder Dod, Vibhuti Singh, james Marsh

January 31, 2013

Presentation TCT 2013

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Presenter: Emmanouil Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc Claeys, Jan Cornel, Philip Aylward, Basil Lewis, Douglas Weaver, Gunnar Brandrup- Wognsen, Susanna Stevens, Lars Wallentin, Stefan James

January 31, 2013

Presentation

High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing PCI

Presenter: 147520|Massimo Leoncini

February 24, 2013

Presentation

Triple Antithrombotic Therapy Is the Independent Predictor of Major Bleeding Complications

Presenter: Y. Naruse

August 26, 2013

Presentation TCT 2013

Heparin Versus Bivalirudin– In-hospital And 30 Day MACE In Patients Having DES Implantation

Presenter: Evan Shlofmitz, Richard Shlofmitz, Simcha Pollack, Elizabeth Cormier, Elizabeth Haag, Nathaniel Reichek

January 31, 2013

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

Presentation

Bivalirudin vs. Heparin Plus a GPI in Pts with NSTEMI Undergoing PCI After Clopidogrel Pretreatment

Presenter: G. Ndrepepa

October 18, 2012

Presentation SOLACI 2016

Mitos e verdades sobre o uso de antiplaquetários na intervenção percutânea

Presenter: Roberto Esporcatte

June 08, 2016

Presentation TCT 2013

Critical Appraisal and Clinical Implications(3)

Presenter: Dean Kereiakes

October 31, 2013

Presentation Fellows 2016

Case 1: Dilemmas in DAPT and PCI Pharmacology

Presenter: Allen Jeremias

April 15, 2016

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

Presenter: Fabio Mangiacapra

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

Presentation TCT 2013

Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With...

Presenter: David Erlinge, Stefan James, Suman Duvvuru, Joseph Jakubowski, Henrik Wanger, Christoph Varenhorst, Udaya Tantry, Patricia Brown, David Small, Brian Moser, Scott Sundseth, Joseph Walker, Kenneth Winters, Paul Gurbel

January 31, 2013

Presentation TCT 2012

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

Presenter: Josef Veselka

October 22, 2012

Presentation TCT 2012

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

Presenter: Paul Gurbel

October 22, 2012

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

Presentation

Prasugrel vs. Clopidogrel for Patients with Unstable Angina or NSTEMI With or Without Angiography

Presenter: Stephen D. Wiviott

August 20, 2013

Presentation TCT 2013

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Presenter: Laura Mauri, Gabriel Steg, Alexis Matteau, Edoardo Camenzind, Eric Boersma, Pascal Vranckx, Patrick Serruys, William O'Neill, Robert Yeh, William Wijns

January 31, 2013

Advertisement

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing PCI

Triple Antithrombotic Therapy Is the Independent Predictor of Major Bleeding Complications

Heparin Versus Bivalirudin– In-hospital And 30 Day MACE In Patients Having DES Implantation

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Bivalirudin vs. Heparin Plus a GPI in Pts with NSTEMI Undergoing PCI After Clopidogrel Pretreatment

Mitos e verdades sobre o uso de antiplaquetários na intervenção percutânea

Critical Appraisal and Clinical Implications(3)

Case 1: Dilemmas in DAPT and PCI Pharmacology

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With...

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Prasugrel vs. Clopidogrel for Patients with Unstable Angina or NSTEMI With or Without Angiography

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content